首页> 外文期刊>Nucleic Acids Research >DNA repair endonuclease ERCC1-XPF as a novel therapeutic target to overcome chemoresistance in cancer therapy
【24h】

DNA repair endonuclease ERCC1-XPF as a novel therapeutic target to overcome chemoresistance in cancer therapy

机译:DNA修复核酸内切酶ERCC1-XPF作为克服癌症治疗中化学耐药性的新型治疗靶标

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

The ERCC1–XPF complex is a structure-specific endonuclease essential for the repair of DNA damage by the nucleotide excision repair pathway. It is also involved in other key cellular processes, including DNA interstrand crosslink (ICL) repair and DNA double-strand break (DSB) repair. New evidence has recently emerged, increasing our understanding of its requirement in these additional roles. In this review, we focus on the protein–protein and protein–DNA interactions made by the ERCC1 and XPF proteins and discuss how these coordinate ERCC1–XPF in its various roles. In a number of different cancers, high expression of ERCC1 has been linked to a poor response to platinum-based chemotherapy. We discuss prospects for the development of DNA repair inhibitors that target the activity, stability or protein interactions of the ERCC1–XPF complex as a novel therapeutic strategy to overcome chemoresistance.
机译:ERCC1-XPF复合物是特定于结构的核酸内切酶,对于通过核苷酸切除修复途径修复DNA损伤至关重要。它还参与其他关键的细胞过程,包括DNA链间交联(ICL)修复和DNA双链断裂(DSB)修复。最近出现了新的证据,这加深了我们对这些角色的需求的理解。在这篇综述中,我们着重于ERCC1和XPF蛋白产生的蛋白质-蛋白质和蛋白质-DNA相互作用,并讨论了它们如何协调ERCC1-XPF的各种作用。在许多不同的癌症中,ERCC1的高表达与对铂类化学疗法的不良反应有关。我们讨论了针对ERCC1-XPF复合物的活性,稳定性或蛋白质相互作用的DNA修复抑制剂的开发前景,将其作为克服化学耐药性的新型治疗策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号